Biotech Terrain May Be Tricky, but It’s Worth Persevering
What are venture capitalists looking for from the biotech and pharma space? It is fair to say that the biotech market is having a challenging time. Much has been written about the lack of M&A activity, disappointing stock performances and the closing of the IPO window as those companies that have managed to get away […]
Five Reasons You Can’t Ignore Payers During Pipeline Development
Could previously launched drugs that significantly missed sales expectations have met a different fate if their manufacturers had accounted for payer perspectives in their early-stage development strategy? Let’s start with some stats. About half of the drugs launched in the last 15 years underperformed analysts’ sales estimates by more than 20%1. Only one-fifth of […]
Better and Cheaper? Digitisation of Medtech Under the Spotlight
Medtech is going digital. Even device makers that are not active in digital health specifically almost always incorporate digital elements in their products – implants containing software to permit remote monitoring or even reprogramming, for instance, or diagnostics and imaging technologies that yield results which integrate automatically with electronic patient records. Digitisation of medical technologies […]
Networking on the Agenda at LSX World Congress
This week saw the return of the LSX World Congress in a real-life environment (London, to be precise). Biotech, medtech and healthtech professionals and investors were clearly delighted to get back to face to face conversations and I joined them to see what the buzz was about. And, if we’re honest, to enjoy a spot […]
